Soluble biological markers in osteoarthritis

In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation...

Full description

Bibliographic Details
Main Authors: Jean-Charles Rousseau, Roland Chapurlat, Patrick Garnero
Format: Article
Language:English
Published: SAGE Publishing 2021-09-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X211040300
id doaj-42d186daa3504822bbcdace1beab3d63
record_format Article
spelling doaj-42d186daa3504822bbcdace1beab3d632021-09-30T21:34:29ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182021-09-011310.1177/1759720X211040300Soluble biological markers in osteoarthritisJean-Charles RousseauRoland ChapurlatPatrick GarneroIn recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks.https://doi.org/10.1177/1759720X211040300
collection DOAJ
language English
format Article
sources DOAJ
author Jean-Charles Rousseau
Roland Chapurlat
Patrick Garnero
spellingShingle Jean-Charles Rousseau
Roland Chapurlat
Patrick Garnero
Soluble biological markers in osteoarthritis
Therapeutic Advances in Musculoskeletal Disease
author_facet Jean-Charles Rousseau
Roland Chapurlat
Patrick Garnero
author_sort Jean-Charles Rousseau
title Soluble biological markers in osteoarthritis
title_short Soluble biological markers in osteoarthritis
title_full Soluble biological markers in osteoarthritis
title_fullStr Soluble biological markers in osteoarthritis
title_full_unstemmed Soluble biological markers in osteoarthritis
title_sort soluble biological markers in osteoarthritis
publisher SAGE Publishing
series Therapeutic Advances in Musculoskeletal Disease
issn 1759-7218
publishDate 2021-09-01
description In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks.
url https://doi.org/10.1177/1759720X211040300
work_keys_str_mv AT jeancharlesrousseau solublebiologicalmarkersinosteoarthritis
AT rolandchapurlat solublebiologicalmarkersinosteoarthritis
AT patrickgarnero solublebiologicalmarkersinosteoarthritis
_version_ 1716862770902728704